Related Experiment Video
Updated: Aug 4, 2025
Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
Published on: January 3, 2013
CD73 Is a Critical Immune Checkpoint in a Molecular Subtype of Pancreatic Cancer
Kathleen DelGiorno1,2,3
1Department of Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee.
Abstract:
Molecular stratification of patients with pancreatic ductal adenocarcinoma (PDAC) has the potential to guide clinical decision-making for therapeutic intervention. Investigating mechanisms by which different molecular subtypes of PDAC form and progress will improve patient responses to existing therapies and aid in identifying new, more specific therapeutic approaches. In this issue of Cancer Research, Faraoni and colleagues identified CD73/Nt5e-generated adenosine as a mechanism of immunosuppression specifically in pancreatic ductal-derived basal/squamous-type PDAC. Using genetically engineered mouse models targeting key genetic mutations to pancreatic acinar or ductal cells and an array of experimental and computational biology approaches, the authors found that adenosine signaling through receptor ADORA2B induces immunosuppression and tumor progression in ductal cell-derived tumors. These data demonstrate how molecular stratification of PDAC in combination with targeted approaches may enhance patient responses to therapy in this deadly cancer. See related article by Faraoni et al., p. 1111.
Insights
Pancreatic cancer (PDAC) subtypes can be identified through molecular stratification. CD73-generated adenosine drives immunosuppression and tumor growth in basal/squamous PDAC, suggesting targeted therapies.
Area of Science:
- Molecular oncology
- Cancer immunology
- Translational research
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with limited therapeutic options.
- Molecular stratification of PDAC holds promise for guiding treatment decisions.
- Understanding PDAC subtype-specific mechanisms is crucial for developing targeted therapies.
Discussion:
- Faraoni and colleagues identified CD73/Nt5e-generated adenosine as a key mediator of immunosuppression in basal/squamous PDAC.
- Adenosine signaling via ADORA2B receptor promotes tumor progression in ductal cell-derived PDAC.
- This study highlights the role of the tumor microenvironment in PDAC progression.
Key Insights:
- Specific molecular subtypes of PDAC exhibit distinct mechanisms of immune evasion.
- Targeting the CD73-adenosine-ADORA2B axis may overcome immunosuppression in basal/squamous PDAC.
- Genetically engineered mouse models are valuable tools for dissecting PDAC pathogenesis.
Outlook:
- Molecular stratification combined with targeted therapies could improve patient outcomes in PDAC.
- Further research into adenosine-mediated immunosuppression may reveal novel therapeutic strategies.
- Translating these findings into clinical practice is essential for combating PDAC.
More Related Videos
08:30Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
Published on: October 9, 2018
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018